TJ0113 study for early-onset Parkinson's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests whether an experimental oral medication (TJ0113) can improve symptoms in people diagnosed with Parkinson's disease before age 50. Participants must already be taking levodopa and keep their current Parkinson's medications unchanged during the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You were diagnosed with Parkinson's disease at age 50 or younger.
- You have been taking levodopa (with or without other Parkinson's medications) and your medication schedule has been stable for at least 3 months.
- You can complete a daily diary to track your 'off' times (when symptoms return).
- You are willing to use effective contraception during the study and for 6 months after.
- You have not had brain surgery for Parkinson's or taken certain drugs (like anticholinergics or amantadine) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
This trial tests several experimental drugs at once to find new treatments for Parkinson's disease. If you have Parkinson's and take medication, you may be able to join and help speed up research.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.